Emyria (ASX:EMD) has moved a step closer to establishing its first Empax clinic in Victoria, with patient treatments still expected to begin in the second quarter of 2026 as key operational and clinical milestones are achieved.
The clinic will deliver medication-assisted therapies for conditions such as treatment-resistant depression and post-traumatic stress disorder, targeting patients who have not responded to conventional care. These therapies may involve carefully controlled use of compounds such as MDMA or psilocybin in combination with structured psychotherapy, delivered under the supervision of trained clinicians.
The company has focused heavily on building clinical capacity ahead of launch, contracting and training 31 therapists across Victoria. This effort is complemented by the training of four psychiatrists, with two more expected to complete training in the coming months.
Operational readiness has also progressed, with Emyria finalising its agreement with site partner Avive Health and preparing the facility for minor fit-out works. Medication supply has already been secured, while discussions with pharmacy partners are ongoing. At the same time, the company is working to integrate clinical governance processes, further reducing execution risk ahead of opening.
A key component underpinning the clinic’s early viability is the establishment of funded patient pathways. Eligible patients will be able to access treatment through private health insurer Medibank and through government support via the Department of Veterans’ Affairs. These dual reimbursement channels are expected to support initial utilisation rates and lessen reliance on self-funded patients.
The Victorian clinic represents an important step in Emyria’s broader national rollout strategy. By expanding into a new state, the company aims to increase its overall treatment capacity and further scale its Empax model, which focuses on delivering evidence-based mental health therapies.
According to Executive Chairman Greg Hutchinson, the company’s progress across clinical, operational and regulatory workstreams has positioned the clinic for an efficient launch phase. With both workforce capacity and funding pathways now largely in place, Emyria expects the new facility to contribute meaningfully to growth while improving access to reimbursable mental health treatments for patients who have not responded to conventional care.